Neurodegeneration – News and Features

A new study suggests estrogen-related receptors could be a key to repairing energy metabolism and muscle fatigue in metabolic disorders like cancer and multiple sclerosis.

A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease, also known as amyotrophic lateral sclerosis (ALS), compared to a placebo.

A new study from Vanderbilt and Pitt links prolonged sedentary behavior to cognitive decline and brain shrinkage in aging adults. The association held even among those who exercised, and was stronger in people with the APOE-e4 gene.

Researchers have introduced DiffSMol, a generative AI model capable of generating realistic 3D structures of small molecules that can serve as promising drug candidates.

Cell clusters called Nageotte nodules have been identified as a crucial component in diabetic pain, offering a target for drugs to help manage diabetic neuropathy.

In this op-ed, Charles Gersbach explores how genetic tuning is emerging as a next-generation approach to modulating gene expression.

Researchers have identified a small molecule that can selectively block cell death. The findings lay the groundwork for next-generation neuroprotective drugs for degenerative conditions, which currently have no cure or treatments.

In a real-world study of 234 Alzheimer’s patients, Washington University researchers found that lecanemab caused severe side effects in just 1%. Patients with very mild symptoms had the lowest risk and greatest benefit.

A University of Georgia study finds that adults with both diabetes and hypertension in midlife show elevated dementia-related biomarkers over time. The risk was especially notable in Black Americans, underscoring health disparities.

A new MIT review highlights how dividing visual processing between hemispheres supports attention and memory. This contralateral organization reduces overload and enhances tracking of multiple objects.